We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Read MoreHide Full Article
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is Harmony Biosciences (HRMY - Free Report) . HRMY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value.
Another notable valuation metric for HRMY is its P/B ratio of 3.03. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 3.34. Over the past 12 months, HRMY's P/B has been as high as 10.51 and as low as 2.34, with a median of 4.82.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. HRMY has a P/S ratio of 2.63. This compares to its industry's average P/S of 5.77.
Investors could also keep in mind Ocuphire Pharma (OCUP - Free Report) , an Medical - Biomedical and Genetics stock with a Zacks Rank of # 2 (Buy) and Value grade of A.
Additionally, Ocuphire Pharma has a P/B ratio of 1.67 while its industry's price-to-book ratio sits at 3.34. For OCUP, this valuation metric has been as high as 6.12, as low as 1.35, with a median of 2.18 over the past year.
These are just a handful of the figures considered in Harmony Biosciences and Ocuphire Pharma's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that HRMY and OCUP is an impressive value stock right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is Harmony Biosciences (HRMY - Free Report) . HRMY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value.
Another notable valuation metric for HRMY is its P/B ratio of 3.03. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 3.34. Over the past 12 months, HRMY's P/B has been as high as 10.51 and as low as 2.34, with a median of 4.82.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. HRMY has a P/S ratio of 2.63. This compares to its industry's average P/S of 5.77.
Investors could also keep in mind Ocuphire Pharma (OCUP - Free Report) , an Medical - Biomedical and Genetics stock with a Zacks Rank of # 2 (Buy) and Value grade of A.
Additionally, Ocuphire Pharma has a P/B ratio of 1.67 while its industry's price-to-book ratio sits at 3.34. For OCUP, this valuation metric has been as high as 6.12, as low as 1.35, with a median of 2.18 over the past year.
These are just a handful of the figures considered in Harmony Biosciences and Ocuphire Pharma's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that HRMY and OCUP is an impressive value stock right now.